Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001049344 | SCV001213390 | likely benign | Duchenne muscular dystrophy | 2024-12-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002339249 | SCV002636573 | uncertain significance | Cardiovascular phenotype | 2021-12-23 | criteria provided, single submitter | clinical testing | The p.P1538L variant (also known as c.4613C>T), located in coding exon 33 of the DMD gene, results from a C to T substitution at nucleotide position 4613. The proline at codon 1538 is replaced by leucine, an amino acid with similar properties. Based on data from gnomAD, the T allele has an overall frequency of 0.001% (2/182904) total alleles studied, with 2 hemizygote(s) observed. The highest observed frequency was 0.002% (2/81555) of European (non-Finnish) alleles. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003145293 | SCV003830070 | uncertain significance | not provided | 2022-10-14 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001273870 | SCV001457455 | uncertain significance | Dystrophin deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |